Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Central Nervous System Tumors Harboring NTRK Fusion”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Looking for participantsNCT05745623
What this trial is testing

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Who this might be right for
Advanced Solid Tumors Harboring NTRK FusionPrimary Central Nervous System Tumors Harboring NTRK Fusion
Beijing InnoCare Pharma Tech Co., Ltd. 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT02637687
What this trial is testing

Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 154
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Testing effectiveness (Phase 2)Active Not RecruitingNCT03213704
What this trial is testing

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent EpendymomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor+30 more
National Cancer Institute (NCI) 9